Investor Presentaiton
Financial Results for FY2022
Segment Information (Core Basis)
Billions of yen
Japan: Lower profit due to
declined gross profit
North America: Profit
decreased since the impact
of higher expenses in
Sumitovant Group and forex
situation exceeded increased
revenue
China: Profit decreased since
the impact of higher expenses
in forex situation
Other Regions: Profit includes
the revenue of $50M under the
license agreement for DSP-
0187
Pharmaceuticals Business
North
Japan
China
America
Other
Regions
Subtotal
Other
Business
Total
Revenue (Sales to customers)
126.1
328.5
39.4
16.8
510.7
44.8
555.5
Cost of sales
65.3
62.4
8.4
5.1
141.3
35.4
176.7
Gross profit
60.9
266.0
31.0
11.6
369.5
9.3
378.8
SG&A expenses
51.8
233.8
11.4
1.6
298.7
7.0
305.6
Core segment profit
9.1
32.2
19.5
10.0
70.8
2.4
73.2
R&D expenses
103.2
2.8
106.1
Core operating profit
(8.0)| 24.3
16.4
Revenue (Sales to customers)
149.9
319.8
38.3
12.2
520.2
39.9
560.0
Cost of sales
78.7
33.6
7.4
6.6
126.3
30.8
157.1
Gross profit
71.3
286.2
30.9
5.5
393.9
9.0
402.9
SG&A expenses
51.7
180.8
11.3
2.3
246.1
5.5
251.6
Core segment profit
19.6
105.4
19.6
3.3
147.8
3.5
151.4
R&D expenses
91.7
2.3
94.0
Core operating profit
57.3
1.2
58.5
Revenue (Sales to customers)
(23.8)
8.7
1.1
4.6
(9.5)
5.0
(4.5)
SG&A expenses
0.1
53.0
0.1
(0.7)
52.6
1.5
54.1
Core segment profit
(10.5)
(73.1)
(0.0)
6.7
(77.0)
(1.1)
(78.1)
R&D expenses
Core operating profit
11.6
0.5
12.1
(65.3)
23.2 (42.1)
FY2022 Results
FY2021 Results
Change
Sumitomo Pharma
Sumitomo Pharma Co., Ltd. All Rights Reserved.
6View entire presentation